Use of Coraxan in Patients with Cardiac and Pulmonary Pathology

Abstract

the article studied the effectiveness of the drug Coraxan in the complex therapy of patients with coronary heart disease (CHD) and arterial hypertension (AH) in combination with chronic obstructive pulmonary disease (COPD). The use of Coraxan in the treatment of patients with concomitant cardiopulmonary pathology leads to a significant decrease in blood pressure (BP) and heart rate (HR), and a decrease in angina attacks. Coraxan increases exercise tolerance (PE).